Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188930. doi: 10.1016/j.bbcan.2023.188930. Epub 2023 Jun 5.
In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies. However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumors and analyzing the underlying mechanisms of combinatorial strategies to counteract these hurdles, we found that complementary therapeutics are needed to improve the scant and transient responses of CAR-T cell monotherapy in solid tumors. Further data, especially data from multicenter clinical trials regarding efficacy, toxicity, and predictive biomarkers are required before the CAR-T combination therapy can be translated into clinical settings.
近几十年来，嵌合抗原受体 T（CAR-T）细胞疗法在血液系统恶性肿瘤患者中取得了显著成功。然而，CAR-T 细胞疗法作为单一疗法未能有效地治疗实体瘤。通过总结 CAR-T 细胞治疗实体瘤的单一疗法所面临的挑战，并分析克服这些障碍的联合策略的潜在机制，我们发现需要互补疗法来改善 CAR-T 细胞治疗实体瘤中稀少且短暂的反应。在 CAR-T 联合治疗转化为临床应用之前，还需要更多的数据，特别是关于疗效、毒性和预测生物标志物的多中心临床试验数据。
